Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
130.00    -0.40 (-0.31%)
Bid:
129.60
Ask:
129.80
Spread: 0.20 (0.154%)
Market Cap: £316.44m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
4th Aug 20227:00 amRNSTransaction in Own Shares
3rd Aug 20227:00 amRNSTransaction in Own Shares
2nd Aug 20227:00 amRNSTransaction in Own Shares
1st Aug 202212:05 pmRNSAkili/Shionogi Begin Ph3 ADHD Study in Japan
1st Aug 20227:00 amRNSTransaction in Own Shares
29th Jul 20227:00 amRNSTransaction in Own Shares
28th Jul 20227:00 amRNSTransaction in Own Shares
27th Jul 20227:00 amRNSTransaction in Own Shares
26th Jul 20227:00 amRNSTransaction in Own Shares
25th Jul 20227:00 amRNSTransaction in Own Shares
22nd Jul 20226:00 pmRNSPDMR Notification RSU Vesting
22nd Jul 20227:00 amRNSTransaction in Own Shares
21st Jul 20227:00 amRNSTransaction in Own Shares
20th Jul 20227:00 amRNSTransaction in Own Shares
19th Jul 20227:00 amRNSTransaction in Own Shares
18th Jul 20227:00 amRNSTransaction in Own Shares
15th Jul 20227:00 amRNSTransaction in Own Shares
14th Jul 202212:05 pmRNSNew Akili Data in Lupus: Better Function in Adults
14th Jul 20227:00 amRNSTransaction in Own Shares
13th Jul 20227:00 amRNSTransaction in Own Shares
12th Jul 20227:00 amRNSTransaction in Own Shares
11th Jul 202212:05 pmRNSPRTC's Akili Announces Public Company BOD Nominees
11th Jul 20227:00 amRNSTransaction in Own Shares
8th Jul 20227:00 amRNSTransaction in Own Shares
7th Jul 20227:00 amRNSTransaction in Own Shares
6th Jul 20227:00 amRNSTransaction in Own Shares
5th Jul 20227:00 amRNSTransaction in Own Shares
4th Jul 20227:00 amRNSTransaction in Own Shares
1st Jul 20227:00 amRNSTransaction in Own Shares
30th Jun 202212:00 pmRNSPRTC Starts LYT-100 IPF Study & Advances LYT-200
30th Jun 20227:00 amRNSTransaction in Own Shares
29th Jun 20227:00 amRNSTransaction in Own Shares
28th Jun 202212:35 pmRNSPRTC's Vedanta Unveils New Manufacturing Facility
28th Jun 20227:00 amRNSTransaction in Own Shares
27th Jun 20227:00 amRNSTransaction in Own Shares
24th Jun 20227:00 amRNSTransaction in Own Shares
23rd Jun 20227:00 amRNSTransaction in Own Shares
22nd Jun 20227:00 amRNSTransaction in Own Shares
21st Jun 202211:35 amRNSGLS: New $15M Plenity Pre-Paid Order; $55M Total
21st Jun 20227:00 amRNSTransaction in Own Shares
20th Jun 20227:00 amRNSTransaction in Own Shares
17th Jun 20227:00 amRNSTransaction in Own Shares
16th Jun 20227:00 amRNSTransaction in Own Shares
15th Jun 20226:00 pmRNSResult of AGM
15th Jun 20227:00 amRNSTransaction in Own Shares
14th Jun 20227:01 amRNSLYT-300 Achieves Proof-of-Principle in Human Study
14th Jun 20227:00 amRNSPost-Acute COVID Resp. Complications Topline Data
14th Jun 20227:00 amRNSTransaction in Own Shares
13th Jun 20227:00 amRNSTransaction in Own Shares
10th Jun 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.